Results showed that GLP-1 receptor agonists and SGLT2 inhibitors were superior in reducing the risk of MACE when compared to DPP-4 inhibitors (HR 086 [082089] and 086 [082090], respectively), but no difference was found between SGLT2 inhibitors and GLP-1 receptor agonists in reducing rate of MACE (HR of 101 (094107)) (68)
Both endogenous GIP (52) and GLP-1 (53) have very short half-lives, measured in minutes, resulting in only a small portion of these active hormones reaching the systemic circulation
"Low Vitamin B12 in Pregnancy Is Associated With Adipose-Derived Circulating miRs Targeting PPAR and Insulin Resistance"
A p-Value Greater Than 0.05 Is Also Significant
C.-E., Goru, R., Yang, Q., Xie, J
Standards of Care in Diabetes 2020